Abstract Thalassemia is an inherited disorder of hemoglobin molecules that is characterized by an imbalance of α-and β-globin chain synthesis. Accumulation of unbound α-globin chains in erythroid cells is the major cause of pathology in β-thalassemia. Stimulation of γ-globin production can ameliorate disease severity as it combines with the α-globin to form fetal hemoglobin. We examined γ-globin-inducing effect of curcuminoids extracted from Curcuma longa L. and their metabolite reduced forms in erythroid leukemia K562 and human primary erythroid precursor cells. The results showed that curcuminoid compounds, especially bisdemethoxycurcumin are potential γ-globin enhancers. We also demonstrated that its reduced analog, hexahydrobisdemethoxycurcumin (HHBDMC), is most effective and leads to induction of γ-globin mRNA and HbF in primary erythroid precursor cells for 3.6±0.4-and 2.0±0.4-folds, respectively. This suggested that HHBDMC is the potential agent to be developed as a new therapeutic drug for β-thalassemia and related β-hemoglobinopathies.
Introduction β-Thalassemia is an inherited disorder of hemoglobin synthesis characterized by the absence or reduction of β-globin chains in erythroid cells [1, 2] . The continued synthesis of α-globin chains, in normal amount, leads to excess α-globins, which do not bind with β-globins and accumulate within erythroid precursors and mature red blood cells. These insoluble aggregates of α-globin cause membrane damage, leading to short red-cell survival. The resulting anemia causes an intense proliferative drive of ineffective erythropoiesis in bone marrow, which leads to skeletal deformities and a variety of growth and metabolic abnormalities. Furthermore, hyperplasia of the bone marrow leads to increased iron absorption and iron loading resulting in progressive iron deposition in the tissue, organ failure, and finally death, if the iron is not removed [1, 2] . The degree of imbalance in α-and β-globin chain synthesis also determines the thalassemia phenotype and the severity level in these patients [3] .
Pharmacological stimulation of fetal hemoglobin (HbF, α 2 γ 2 ) production is a potential therapeutic approach for β-thalassemia [1, 4] . The rationale for this approach is based on the observation that γ-globins can combine with α-globins and compensate for the reduced amount of β-globin synthesis in β-thalassemia. A number of clinical trials have investigated several potential HbF inducers. The current drugs for Hb F induction, such as 5-azacytidine, hydroxyurea, and butyric acid, have low efficacy and specificity, and some agents are potential carcinogens and associated with high toxicity [5, 6] . Therefore, the identification of new pharmacological HbFinducing agents with greater efficacy and less toxicity, is urgently needed for treatment of β-thalassemia patients. A number of plant extracts and plant constituents have been reported to induce HbF expression [7] . Curcuma longa L. is a medicinal plant used widely as Asian traditional herbal remedy and dietary spice. Its curcuminoid constituents are known to have the biological activities as antioxidant, antiinflammation, and anticarcinogen [8, 9] . This study will explore the γ-globin expression and HbF-inducing effect of curcuminoids from C. longa extract. Their curcuminoid constituents, curcumin, demethoxycurcumin, and bisdemethoxycurcumin (BDMC) and the metabolite-reduced analogs of these curcuminoids were also assessed, aiming to find a new drug for treatment of hemoglobinopathies, especially β-thalassemic disease.
Materials and methods

Curcuminoids and reduced curcuminoid analogs
The three natural curcuminoids, curcumin, demethoxycurcumin, and BDMC, were obtained from the rhizomes of C. longa as described previously [10] . Tetrahydrobisdemethoxycurcumin (THBDMC), hexahydrobisdemethoxycurcumin (HHBDMC), and octahydrobisdemethoxycurcumin (OHBDMC) were prepared by catalytic hydrogenation of BDMC in the same manner described for the preparation of reduced analogs of curcumin [10, 11] . The mixture of crude products was chromatographed to afford THBDMC (60 mg, 60 %), HHBDMC (22 mg, 22 %), and OHBDMC (10 mg, 10 %). The synthesized analogs were characterized by spectroscopic techniques including IR, NMR, and mass spectrometry. The 1 H NMR data of THBDMC were consistent with those reported previously [12] whereas those of HHBDMC and OHBDMC were consistent with their spectroscopic data (see "Electronic supplementary material").
Stock compound solutions
The curcuminoids and analogs were dissolved in 100 % dimethyl sulfoxide (DMSO) into a final concentration of 10 mM as the stock solution and kept at 4°C in the dark. Hemin (Sigma-Aldrich, St. Louis, MO) solution was freshly prepared by dissolving in DMSO to a final concentration of 5 mM and filtered through a 0.45-μm-filter paper. Cisplatin (Pfizer (Perth), Bentley, Australia), 3.3 mM stock solution, was prepared by dissolving in distilled water and filtered through a 0.45 μm filter paper before storage at 4°C.
Cell lines and treatment
A stable reporter cell line, K562::Δ G γ-A γ EGFP cells, harboring green fluorescent protein gene in-frame replacement of the G γ-and A γ-globin coding sequence in the intact human β-globin locus was used for screening of HbF inducer [13] . These cells and K562 cells were cultured in RPMI1640 supplement with 20 % fetal bovine serum (FBS, GIBCO-Invitrogen, Carlsbad, CA). The cells were treated with or without the test compounds. EGFP expression and HbF staining were analyzed by FACS after 5 days of treatment. The untreated cells were used as the negative control, and cells treated with 50 μM hemin and 20 μM cisplatin as positive controls.
Human erythroid primary cells culture Informed consent forms for ethical clearance permitted by the Institutional Review Board of Mahidol University, Thailand, were signed by all healthy volunteers before 20-ml peripheral blood samples were collected. CD34-positive cells were isolated by immunomagnetic-positive cell selection using anti-CD34 immunomagnetic bead (Miltenyi Biotech, Bergisch Gladbach, Germany). Cells were cultured by two-phase methods as previously described [14] . Briefly, the cells were initially cultured in phase I culture medium composed of Iscoves modified Dulbecco medium (IMDM, GIBCO-Invitrogen) and supplemented with 30 % FBS, 0.01 % bovine serum albumin (BSA, GIBCO-Invitrogen), 1 %L-glutamin, 10 μg/ml cyclosporin A (Novartis, East Hanover, NJ), 25 ng/ml human interleukin-3 (IL-3, Promokine, Germany), 50 ng/ml recombinant human stem cell factor (rhSCF, Promokine), and 0.1 U/ ml recombinant human erythropoietin (rhEPO, EPREX, Belgium). On day7, cells were subcultured in phase II culture media contained IMDM and supplemented with 30 % FBS, 1 % BSA, 1 μM hydrocortisone (Sigma-Aldrich), 0.1 mM β-mercaptoethanol (GIBCO-Invitrogen), 0.1 ng/ml IL-3, and 5 U/ml rhEPO. The cells were treated with curcuminoids on day7 and harvested for analysis of globin gene expression and HbF production on day14.
Cell viability measurement
The viability of cells was measured by using an annexin V/PI apoptosis kit (BD Bioscience, San Jose, CA). Positive cell staining was detected by FACSCalibur flow cytometer and analysis is performed using BD Cell Quest software (BD Bioscience). The percentage of cell viability was calculated based on the number of non-positive cells.
Analysis of EGFP expression and HbF production
The induction of EGFP expression in curcuminoids treated K562::Δ G γ-A γ EGFP cells was measured by FACSCalibur flow cytometer (BD Bioscience) and Cell Quest software (BD Bioscience). The levels of HbF production were determined by staining with fluorescein isothiocyanate (FITC)-conjugated monoclonal antibody against HbF (BD Bioscience) and analyzed by FACSCalibur flow cytometer. The mean fluorescent intensity of EGFP expression or HbF production was measured and used for calculation of the fold change response to various inducing agents between the induced and non-induced cells.
Globin mRNA analysis
Total RNA was extracted by TriReagent® (Molecular Research Center, Cincinnati, OH) according to the manufacturer instructions. One microgram of total RNA was reverse-transcribed to cDNA using Oligo-dT primer and Super-Script TM II Reverse Transcriptase (Invitrogen, USA). Multiplex quantitative real-time reverse transcription polymerase chain reaction (RT-qPCR) for quantification of α-, β-, and γ-mRNA was performed using TaqMan TM One-Step RT-PCR Master Mix kit (Bio-Rad Laboratories, Hercules, CA) previously described [15] . The globin gene expression between treated and untreated samples was calculated as 2 −ΔΔCt relatively to the reference gene, β-actin.
Statistic analyses
Data are shown as mean±SD of three independent measurements and statistically analyzed using Student's t test. Values of significance were considered at P<0.05.
Results
Induction of γ-globin gene expression using K562::Δ G γ-A γEGFP reporter cells treated with C. longa extracts and its reduced analogs C. longa crude extract was firstly screened to investigate its activity as γ-globin and HbF enhancer by using the K562::Δ G γ-A γEGFP reporter cells. This cell line has previously been shown to respond to known HbF inducers as shown by the increased EGFP expression linked to γ-globin promoter activity [13] . The result showed that 30 μg/ml C. longa crude extract enhanced EGFP expression by 1.4±0.5-fold with 89 % cell viability when compared to untreated cells (Fig. 1a) . This result prompted us to continue to screen individual curcuminoid compounds: curcumin, demethoxycurcumin, and bisdemethoxycurcumin (BDMC). Interestingly, all curcuminoid compounds enhanced γ-gene promoter activity in a dose-dependent manner, as shown by induced EGFP expression. BDMC was found to give the highest EGFP expression at 30 μM with a 3.5±0.4-fold increase, compared to the untreated control (Fig. 1b , Table 1 ).
Previous studies of curcumin metabolites in rodents and humans have revealed that curcumin undergoes rapid metabolism and formation of reduced metabolites. Data from the individual curcuminoid compound initiated our interest to study BDMC and its metabolite reduced analogs, THBDMC, HHBDMC, and OHBDMC. The result showed that the parent compound and its reduced analogs enhanced EGFP expression in K562::Δ G γ-A γ EGFP cells in a dosedependent manner (Fig. 2a) . The most effective compound was HHBDMC at 40 μM, which gave a significant fold change, 4.2±0.1, when compared with the untreated control, whereas 30 μM BDMC, 40 μM THBDMC, and 50 μM OHBDMC moderately enhanced EGFP expression by 3.5± 0.4-, 3.7± 0.2-, and 2.2± 0.3-fold, respectively (Fig. 2a , Table 1 ). Moreover, all curcuminoids compounds were found to have less toxicity, with more than 80 % cell viability, when compared to the positive control such as 50 μM hemin (60.8±9.8 %) and 20 μM cisplatin (76.3± 6.3 %).
Induction of HbF production and γ-globin gene expression in K562 cells
To confirm the γ-globin-inducing effect of curcuminoids, the native erythroid leukemia (K562) cells were exposed to BDMC, THBDMC, HHBDMC, and OHBDMC at the concentration ranging from 10 to 50 μM. After 5 days, cells were harvested to analyze the HbF production, γ-globin expression, and cell viability. The results shown in the native erythroid leukemia cell lines were consistent with those of the K562::Δ G γ-A γ EGFP reporter cells, which demonstrated that 40 μM HHBDMC was most effective, and HbF production was induced up to 2.1±0.2-folds when compared with that of the untreated K562 cells (Fig. 2b , Table 1 ), while 20 μM cisplatin and 50 μM hemin induced HbF production by 1.9±0.2-and 2.1±0.3-fold, respectively, when compared to the untreated cells (Fig. 2b) . In addition, cell viability was more than 80 % suggesting that all natural compounds at the highest dose (up to 40 μM) was still less toxic than the positive control, 66.8±2.5 % with 50 μM hemin and 78.8±3.5 % with 20 μM cisplatin.
Alteration of α-and γ-globin gene expression in K562 cells was also found to be dose dependent with the test curcuminoid compounds. The most prominent result was that of the 30 μM HHBDMC, which significantly increased γ-globin mRNA level to 3.6±0.4-folds when compared to the untreated cells, whereas the other natural compounds increased γ-globin expression at a lower level (Fig. 2c) . The induction of γ-globin mRNA levels was consistent with the increased HbF levels, and EGFP expression following OHBDMC THBDMC, BDMC, and HHBDMC treatment, which are in the order of increasing activity. This study also showed that the positive controls, 20 μM cisplatin and 50 μM hemin, significantly increased γ-globin gene expression when compared to the untreated cells by 3.9±0.4-and 4.0±0.5-fold, respectively (Fig. 2c) .
Induction of HbF production and γ-globin gene expression in the primary human erythroid cell cultures
The effect of BDMC and its reduced form were assessed for the induction of human γ-globin gene and HbF production in erythroid progenitor cells culture derived from healthy volunteers. Based on the results in K562 cells, we decided to investigate only BDMC, THBDMC, and HHBDMC. The human erythroid progenitor cells were treated with 10 to 30 μM of the test compounds at day7 and harvested for globin mRNA expression study as well as HbF production on day14. A dose-dependent induction of HbF production was observed in erythroid precursor cells treated with BDMC and its reduced metabolites (Fig. 3) We also investigated the level of globin mRNA expression in human erythroid cells following exposure with the test curcuminoid compounds. The result showed that all natural compounds increased all three globin mRNA levels, but the effect was more pronounce in γ-globin mRNA level, especially 20 μM HHBDMC, which significantly increased γ-globin gene expression by 3.2±0.2-fold, which is similar to 20 μM cisplatin-treated (3.1 ± 0.2-fold) and 50 μM hemin-treated (3.4±0.1-fold) cells (Fig. 3b) , while its parent compound, BDMC, and the other reduced analogs, THBDMC, were less effective at γ-globin gene induction.
Discussion
The identification of bioactive compound isolated from C. longa is a promising strategy to develop a new pharmaceutical from medicinal plant. Our data suggested that the phytochemicals profiles of curcuminoids can induce γ-globin expression and, more importantly, increase HbF production in human erythroid cell culture. Among the three curcuminoids, curcumin, demethoxycurcumin, and BDMC, the last curcuminoid was the most effective compound that enhanced γ-globin mRNA expression and HbF synthesis. We found that not only BDMC but also its reduced analogs enhanced EGFP expression when these compounds were tested in all three types of erythroid cells, K562::Δ G γ-A γ EGFP reporter cell line, native K562, and primary human erythroid cell culture. HHBDMC was the most effective reduced analog of BDMC that induced γ-globin expression and HbF production.
Since BDMC was more active than demethoxycurcumin, it was thus concluded that introduction of one methoxyl group on the aromatic ring to give demethoxycurcumin structure resulted in a decreased activity. BDMC was therefore chosen as a structure lead to further structural Toxicity studies, either in animal or in human showed that there is no toxicity at a dosage of 2,000 or 8,000 mg/kg/day curcumin, respectively. In addition, many recent studies have shown that curcumin has very poor bioavailability due to poor absorption and rapid metabolism. The maximum concentration can be detected within 1-2 h after 4,000 mg/kg oral uptake of curcumin. For dose escalation in 34 human subjects, only in the subjects who have administered 10,000 or 12,000 mg as single oral, the low level of curcumin in serum but not in plasma can be detected, and no toxicity appeared in the high dose [16] [17] [18] . The study also showed that not only the parent compounds but also their metabolite reduced analogs have the neuroprotective activity. That is shown by inhibited nitric oxide (NO) production and the decreased mRNA expression level of inducible NO synthase from lipopolysaccharide exposed in HAPI microglial cells [19] .
A number of plant extracts and plant constituents have been reported to induce HbF expression such as resveratrol from grape [20] , angelicin from Aegle marmelos [21] , labdane diterpenes from Curcuma comosa [22] , citropten and bergapten from Citrus bergamia [23] . This is the first study that demonstrated γ-globin expression and HbF-inducing properties of C. longa extract, curcuminoids and reduced analogs in human erythroid cells. Recent studies suggested that curcuminoids are a potent epigenetic modification agent by interaction with histone deacetylases (HDAC), histone acetyltransferases (HAT), and DNA methlytranferase I (DNMT1) [24, 25] . The studies in human cancer cells showed that the mode of action of curcumin was through direct interaction with target proteins as well as epigenetic modulation of target genes in a time-and concentration-dependent manner. Curcumin covalently binds with DNMT1 and blocks the catalytic activity, leading to exertion of its global DNA hypomethylation in a leukemia cell line [26] [27] [28] .
In this study, we report for the first time that curcuminoids can induce γ-globin expression and, more importantly, increase HbF production in human erythroid cell culture. We demonstrate that HHBDMC was most effective in two independent assay systems. Based on our findings, the analysis of the effects of HHBDMC and related compounds in erythroid cells derived from thalassemia patients is warranted. Mechanistically, curcuminoids have been shown to be potent epigenetic modifying agent by interacting with HDACs, HAT, and DNMT1. Further studies are needed to clarify the mechanism of γ-globin inducer of these compounds in order to develop targeted therapeutic strategies for hemoglobin disorders such as β-thalassemia and sickle cell disease.
